Member Info for shatter

Cash burn is still an issue . Perhaps enough for another 6 months? Missed targets again ! On the bright side we are still alive and kicking, barely.....

Dragon 101 over on the SCLP site amongst others has posted some interesting articles that refer to the CAR-t advances and Novartis which will directly impact OXB, hopefully.

I have a sneaky suspicion that this maybe delisted and go private in the not to distant future. What is salvageable can be split amongst the few that are left with an interest. Basically just a calamity from start to finish....

I would not take much notice of Peel Hunt...perhaps a little biased...

Probably already built into the price. Every little helps...not long for results.

The recent 18 million fund raising is now worth 9 million.... great investment eh

Interesting to see how the results pan out next month. Hopefully some cash in the bank.

Summer can be a stagnant period for shares but heap on Brexit woes and Trumps muscle flexing and it explains the state of the market... as you say give this a few months..

Not a dickey bird since the open offer result . Last one out turn off the lights must be on the horizon shortly...the open offer is perhaps severance pay ? It’s slowly limping to a sad conclusion now by the looks of things....I suspect they are ready to post an Rns stating that they have done everything possible but market conditions were against them. Onwards and upwards....sure it’s only money :-)

A completely non-biased view. Will not be topping up just quite yet...

Maybe not too many employed in the near future.....

Good name.. no idea of the share buy back value so far. It has not helped us private investors in the least. To buy back 5-6 % of your shares will never make much of a difference to a companies sp. The bod will reward themselves for this great idea...only one winner

The bod are exercising their options and subsequently flogging the lot ! Now that’s confidence inspiring ?

Oxford, UK - 10 August 2018:Â Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 August 2018 Jason Slingsby, Chief Business Officer, exercised 5,334 options at 487.4p, exercised 7,139 options at 490.0p and 6,155 options at 487.4p and sold all of the resulting shares at 890.1p.

Dropping on tiny volumes....

Yep, sp behaving in a very odd way. The bod were hoping that the sp would stop acting so irrationally but not the case. Bound to put off some investors ?

They reckon out of all the U.K. banks they are in a better position than most to weather the Brexit storm with their cash reserves. Time to top up me thinks.

Aviva PLC (LON:AV.) saw its first-half operating profit slip as a result of significantly increased weather-related claims, a poor Canadian performance, and the impact of disposals, but the insurer still hiked its dividend by 10%.

For the six months to 30 June 2018, the FTSE 100-listed group said its operating profit dipped by 2% to £1.44bn, down from £1.47bn a year earlier, although excluding disposals its operating profit was up 4%.

Reckon we will wake up one morning to find that this has been suspended and will be taken private. With the debt and general lack of progress it seems the obvious path for the bod.

Someone should put the cork back in the well and have the decency to shut up office. And yes, I do own shares in this, unfortunately !